LYEL vs DBVT vs CABA vs SANA vs IMVT

Analysts rate DBV Technologies S.

A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +84. 4%, compared to -94. 3% for Lyell Immunopharma, Inc. (LYEL). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus LYEL's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Sana Biotechnology, Inc. 's 2. 66β — meaning SANA is approximately 111% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 38% for Sana Biotechnology, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Cabaletta Bio, Inc.

grew EPS 29. 9% year-over-year, compared to -1126. 0% for Lyell Immunopharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DBV Technologies S.

A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -7623. 6% for Lyell Immunopharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -5660. 4% for LYEL. At the gross margin level — before operating expenses — DBVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Immunovant, Inc.

(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+190. 9% 10Y return). Sana Biotechnology, Inc. (SANA) carries a higher beta of 2. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +190. 9%, SANA: -90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.